Healthcare Dive17h
A new, non-opioid pain drug is here. Getting it to patients could be agony.
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
Hosted on MSN20h
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, ...
FiercePharma21h
Vertex lays out plan to increase access and launch non-opioid pain reliever Journavx
For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
BioPharma Dive21h
Vertex COO Arbuckle to step down later this year
Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...
Piper Sandler maintains Vertex stock Overweight with $533 target
Piper Sandler expressed continued confidence in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), maintaining an Overweight ...